| 方和慧,徐 婷,王晓月,刘 娜,程弯弯,徐 姝.鸦胆子油乳注射液联合TP方案对晚期非小细胞肺癌患者肿瘤标志物和血清TAP、Hsp90α的影响[J].现代生物医学进展英文版,2024,(9):1682-1685. |
| 鸦胆子油乳注射液联合TP方案对晚期非小细胞肺癌患者肿瘤标志物和血清TAP、Hsp90α的影响 |
| Effects of Brucea Javanica Oil Emulsion Injection Combined with TP Regimen on Tumor Markers and Serum TAP and Hsp90α in Patients with Advanced Non-Small Cell Lung Cancer |
| Received:December 12, 2023 Revised:December 31, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.09.016 |
| 中文关键词: 鸦胆子油乳注射液 TP方案 晚期非小细胞肺癌 肿瘤标志物 TAP Hsp90α |
| 英文关键词: Brucea javanica oil emulsion injection TP regimen Advanced non-small cell lung cancer Tumor markers TAP Hsp90α |
| 基金项目:江苏省"六个一工程"拔尖人才科研项目(LYG2019006) |
|
| Hits: 318 |
| Download times: 221 |
| 中文摘要: |
| 摘要 目的：探讨鸦胆子油乳注射液联合顺铂+紫杉醇（TP）方案对晚期非小细胞肺癌（NSCLC）患者肿瘤标志物和血清肿瘤异常蛋白（TAP）、热休克蛋白90α（Hsp90α）的影响。方法：纳入南京医科大学附属脑科医院呼吸院区呼吸科2018年3月~2020年3月期间收治的100例晚期NSCLC患者，分组选用随机数字表法，其中研究组50例，TP方案基础上联合鸦胆子油乳注射液治疗，对照组50例，仅TP方案治疗。对比两组疗效、血清肿瘤标志物、TAP、Hsp90α和不良反应发生率，随访3年，采用生存曲线分析两组的累积生存率。结果：研究组的客观缓解率、疾病控制率均高于对照组（P<0.05）。治疗4个周期后，研究组癌胚抗原（CEA）、鳞状上皮细胞癌抗原（SCC）、TAP、细胞角蛋白19片段（CYFRA21-1）、Hsp90α低于对照组（P<0.05）。两组不良反应发生率组间对比未见差异（P>0.05）。两组生存资料之无进展生存时间（PFS）和总生存时间（OS）经LogRank检验，均有显著性差异（P＜0.05）。结论：鸦胆子油乳注射液联合TP方案治疗晚期NSCLC患者，可有效调节肿瘤标志物和血清TAP、Hsp90α水平，延长患者生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of brucea javanica oil emulsion injection combined with cisplatin and paclitaxel (TP) regimen on tumor markers, serum tumor abnormal protein (TAP) and heat shock protein 90α(Hsp90α)in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 100 patients with advanced NSCLC who were admitted to the Department of Respiratory, Respiratory Hospital Area of Brain Hospital Affiliated to Nanjing Medical University from March 2018 to March 2020 were included. Randomized number table method was used in the groups, among them, 50 cases in the study group were treated with on the basis of TP regimen combined with brucea javanica oil emulsion injection, and 50 cases in the control group were treated with TP regimen alone. Efficacy, serum tumor markers, TAP, Hsp90α and incidence of adverse reactions were compared in the two groups. After 3 years of follow-up, the cumulative survival rate in the two groups was analyzed by the survival curve. Results: The objective remission rate and disease control rate in the study group were higher than those in the control group (P<0.05). 4 cycles after treatment, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), TAP, cytokeratin 19 fragment (CYFRA21-1) and Hsp90α in the study group were lower than those in the control group(P<0.05). There was no difference in the incidence of adverse reactions in the two groups (P>0.05). The progression-free survival time (PFS) and overall survival time (OS) in the two groups were tested by LogRank, all had significant differences(P<0.05). Conclusion: Brucea javanica oil emulsion injection combined with TP regimen in the treatment of patients with advanced NSCLC can effectively regulate tumor markers and serum TAP and Hsp90α levels, and prolong the survival rate of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
